Medicure Inc Declines A lot Today, Is Now One of The Worst Performer

 Medicure Inc Declines A lot Today, Is Now One of The Worst Performer

The stock of Medicure Inc (CVE:MPH) is a huge mover today! About 6,300 shares traded hands. Medicure Inc (CVE:MPH) has risen 6.00% since October 23, 2016 and is uptrending. It has outperformed by 1.44% the S&P500.
The move comes after 7 months negative chart setup for the $127.52M company. It was reported on Nov, 22 by Barchart.com. We have $6.58 PT which if reached, will make CVE:MPH worth $8.93 million less.

More recent Medicure Inc (CVE:MPH) news were published by: Midasletter.com which released: “S&P/TSX Venture Composite Index Movers: GoldMoney Inc., Medicure Inc …” on February 02, 2016. Also Seekingalpha.com published the news titled: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” on February 17, 2016. Prnewswire.com‘s news article titled: “Medicure to Hold Investor Call on November 21, 2016” with publication date: November 18, 2016 was also an interesting one.

Medicure Inc. is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The company has a market cap of $127.52 million. The Firm operates in the biopharmaceutical industry segment. It has a 24.92 P/E ratio. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc.

MPH.V Company Profile

Medicure Inc. (Medicure), incorporated on February 23, 2000, is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The Firm operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. The Firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment